Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokers have set a 1 year consensus price objective of $10.00 for the company and are expecting that the company will post ($0.17) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Titan Pharmaceuticals an industry rank of 77 out of 256 based on the ratings given to related companies.
A number of brokerages have commented on TTNP. Maxim Group began coverage on shares of Titan Pharmaceuticals in a research note on Wednesday, June 26th. They issued a “buy” rating and a $4.00 target price on the stock. ValuEngine upgraded shares of Titan Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.
A hedge fund recently raised its stake in Titan Pharmaceuticals stock. Geode Capital Management LLC lifted its holdings in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) by 256.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 341,474 shares of the specialty pharmaceutical company’s stock after purchasing an additional 245,565 shares during the period. Geode Capital Management LLC owned about 2.63% of Titan Pharmaceuticals worth $76,000 at the end of the most recent quarter. 5.06% of the stock is currently owned by institutional investors.
TTNP stock traded down $0.29 during mid-day trading on Friday, reaching $0.78. The company had a trading volume of 812,319 shares, compared to its average volume of 161,201. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.12 and a quick ratio of 1.86. The stock has a market cap of $15.27 million, a P/E ratio of -0.99 and a beta of 0.99. The business has a 50 day moving average of $1.25. Titan Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $5.64.
Titan Pharmaceuticals (NASDAQ:TTNP) last issued its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.08). The company had revenue of $0.95 million during the quarter. Titan Pharmaceuticals had a negative return on equity of 311.18% and a negative net margin of 168.23%. Equities analysts anticipate that Titan Pharmaceuticals will post -0.68 EPS for the current fiscal year.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.
Featured Story: Dead Cat Bounce
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.